While some Silicon Valley tech titans infuse themselves with rejuvenating blood within the hopes of dwelling longer, others work on accelerating drug discovery to remedy precise illnesses. Dr. Monica Berrondo and her mom, Susana Kaufmann, based Macromoltek in 2011 to help pharmaceutical corporations with the remedy and prognosis of infectious illnesses and varied sorts of cancers. The duo can be graduating from Y Combinator’s present batch (Winter 2018) later this month with $120,000 in funding.
Based in Austin, Texas, Macromoltek supplies a molecular modeling software program to research potential antibody drug candidates. The startup helps pharmaceutical corporations design new antibodies to deal with infections and illnesses by predicting the buildings of those antibodies. It then makes use of proprietary algorithms to optimize the choice course of. According to Dr. Berrondo, who's the CEO, this helps pharmas slender down their analysis and goal the molecules which are probably to succeed.
Above: Image of Herceptin (trastuzumab), an antibody that's used to deal with breast most cancers.
Image Credit: Macromoltek
Although the startup was initially modeled as a software-as-a-service (SaaS) platform, Berrondo realized it was more practical to work with corporations immediately by means of collaboration and cost them for the companies. The charges depend upon the quantity and complexity of molecules being examined or designed. Macromoltek says it will get royalties ought to the drug be efficiently commercialized.
The startup is at present working with a handful of pharma corporations throughout the U.S., the U.Okay., Switzerland, Germany, and China. It declined to call any prospects at this stage.
Prior to founding Macromoltek, Berrondo, who has a background in chemical engineering and biophysics, labored immediately with pharma corporations to coach their staff on the best way to use tutorial molecular modeling software program.
“What I found was that the software packages were so hard to use, employees needed several retraining sessions,” she mentioned, in an interview with VentureBeat. “And the findings weren’t really applicable to real-life cases. So I thought, ‘What if we rewrote something that really focuses on and tailors to industry problems?'”
Berrondo subsequently started growing, testing, and benchmarking an algorithm to foretell buildings of antibody sequences. So far, the chief govt and her staff have labored on infectious illnesses just like the Zika virus and Burkholderia, in addition to many sorts of metastatic cancers.
Seeing as the typical drug takes as much as 15 years and $2.5 billion to develop, drug discovery platforms are important to speed up the method and minimize down prices. Atomwise, one other YC graduate, launched a analysis program to speed up drug discovery with AI final 12 months. Genetic diagnostic platforms like Sequoia-backed MedGenome and Sofia Genetics are additionally garnering consideration.
To date, Macromoltek has obtained near $1 million in grants from the National Science Foundation for its analysis. The startup at present has 5 staff.
</div>